[go: up one dir, main page]

MA33043B1 - Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie - Google Patents

Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie

Info

Publication number
MA33043B1
MA33043B1 MA34088A MA34088A MA33043B1 MA 33043 B1 MA33043 B1 MA 33043B1 MA 34088 A MA34088 A MA 34088A MA 34088 A MA34088 A MA 34088A MA 33043 B1 MA33043 B1 MA 33043B1
Authority
MA
Morocco
Prior art keywords
type
diabetes
hyperglycemia
sglt
inhibitor
Prior art date
Application number
MA34088A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Eickelmann
Michael Mark
Leo John Seman
Leo Thomas
Uli Broedl
Rolf Grempler
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33043(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33043B1 publication Critical patent/MA33043B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

L'invention porte sur le traitement ou la prévention d'un ou plusieurs états pathologiques parmi le diabète sucré de type 1, le diabète sucré de type 2, une intolérance au glucose et une hyperglycémie, à l'aide d'un inhibiteur SGLT-2. De plus, la présente invention porte sur des méthodes de prévention ou de traitement des troubles métaboliques et d'états pathologiques apparentés.
MA34088A 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie MA33043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15231809P 2009-02-13 2009-02-13
PCT/EP2010/051734 WO2010092123A1 (fr) 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabète sucré de type 1, du diabète sucré de type 2, d'une intolérance au glucose ou d'une hyperglycémie

Publications (1)

Publication Number Publication Date
MA33043B1 true MA33043B1 (fr) 2012-02-01

Family

ID=42008536

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34088A MA33043B1 (fr) 2009-02-13 2010-02-11 Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie

Country Status (29)

Country Link
US (8) US20110046087A1 (fr)
EP (2) EP2396005B1 (fr)
JP (3) JP5896276B2 (fr)
KR (2) KR20110118668A (fr)
CN (2) CN104138370A (fr)
AP (1) AP2011005795A0 (fr)
AR (1) AR075424A1 (fr)
AU (1) AU2010212865A1 (fr)
BR (1) BRPI1013640A2 (fr)
CA (1) CA2751833C (fr)
CL (1) CL2011001757A1 (fr)
CO (1) CO6410306A2 (fr)
EA (1) EA021796B1 (fr)
EC (1) ECSP11011275A (fr)
FI (1) FI2396005T3 (fr)
GE (1) GEP20146120B (fr)
HK (1) HK1203814A1 (fr)
IL (1) IL213723A0 (fr)
MA (1) MA33043B1 (fr)
MX (2) MX344264B (fr)
MY (1) MY161472A (fr)
NZ (1) NZ594485A (fr)
PE (1) PE20120002A1 (fr)
PH (1) PH12016501607B1 (fr)
SG (2) SG10201600204YA (fr)
TN (1) TN2011000413A1 (fr)
TW (1) TWI478935B (fr)
UA (1) UA106365C2 (fr)
WO (1) WO2010092123A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360165A3 (fr) * 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Derives du benzol substitues par un glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de production
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
RU2008113050A (ru) * 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2054426A1 (fr) * 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Dérivés de cyclopropyl-benzène à substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leur utilisation en tant qu'inhibiteurs de sglt et leur procédé de fabrication
EP2086991A1 (fr) * 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH FORME CRISTALLINE DU 4-(ß-D-GLUCOPYRANOS-1-YL)-1-MÉTHYL-2-[4-((S)-TÉTRAHYDROFURAN-3-YLOXY)BENZYL]-BENZÈNE, PROCÉDÉ POUR LA PRÉPARATION DE CELLE-CI ET UTILISATION DE CELLE-CI POUR PRÉPARER DES MÉDICAMENTS
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
WO2009068617A1 (fr) 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh Dérivés de 1,5-dihydro-pyrazolo(3,4-d)pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a pour le traitement de troubles du snc
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
WO2009143021A1 (fr) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Procédé pour traiter et prévenir des calculs rénaux à l'aide d'un inhibiteur de sglt2 et composition le contenant
WO2010009243A1 (fr) 2008-07-15 2010-01-21 Theracos, Inc. Dérivés de benzylbenzène deutérés et procédés d’utilisation
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
WO2010092126A1 (fr) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant des dérivés de glucopyranosyl diphényl-méthane, sa forme posologique galénique, son procédé de préparation et ses utilisations pour une régulation glycémique améliorée chez un patient
CN102307577A (zh) 2009-02-13 2012-01-04 贝林格尔.英格海姆国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
BRPI1013640A2 (pt) 2009-02-13 2019-09-24 Boehringer Ingelheim International Gmbh composicao farmaceutica, metodos para o tratamento e usos dos mesmos
PL2414363T3 (pl) 2009-03-31 2014-06-30 Boehringer Ingelheim Int Pochodne 1-heterocyklilo-1,5-dihydro-pirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako modulatorów PDE9A
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
JP5736377B2 (ja) 2009-09-30 2015-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
DK2603511T3 (en) 2010-08-12 2017-05-08 Boehringer Ingelheim Int 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO- [3,4-D] PYRIMIDIN-4-ON DERIVATIVES AND THEIR USES AS PDE9A INHIBITORS
WO2012041898A1 (fr) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CA2837627A1 (fr) * 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Inhibiteurs de sglt-2 pour traiter des troubles metaboliques chez des patients traites avec des agents neuroleptiques
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102627535A (zh) * 2012-03-31 2012-08-08 天津药物研究院 含1,1-二苯基环丙基结构的化合物的制备方法
WO2014161836A1 (fr) * 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Traitement de troubles métaboliques chez des équidés
CA2812016A1 (fr) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
PL3082829T3 (pl) * 2013-12-17 2021-09-06 Boehringer Ingelheim Vetmedica Gmbh Inhibitory sglt2 do leczenia zaburzeń metabolicznych u zwierząt kotowatych
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
US10603300B2 (en) * 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
HUE068880T2 (hu) 2014-04-01 2025-02-28 Boehringer Ingelheim Vetmedica Gmbh Hipofízis pars intermedia diszfunkció kezelése lófélékben
WO2016036077A1 (fr) * 2014-09-02 2016-03-10 엘지전자 주식회사 Appareil de réception de diffusion générale, procédé d'exploitation d'un appareil de réception de diffusion générale, appareil imbriqué s'imbriquant avec un appareil de réception de diffusion générale, et procédé d'exploitation d'un appareil imbriqué
KR102539788B1 (ko) 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
US20180104268A1 (en) * 2015-04-30 2018-04-19 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
US20160375113A1 (en) * 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
LT3341024T (lt) 2015-08-27 2025-01-10 Boehringer Ingelheim Vetmedica Gmbh Skystos farmacinės kompozicijos, apimančios sglt-2 inhibitorius
WO2017064193A1 (fr) * 2015-10-15 2017-04-20 Boehringer Ingelheim International Gmbh Inhibiteur de sglt -2 destiné à être utilisé dans le traitement d'une myopathie métabolique
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
WO2019087239A1 (fr) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート Agent thérapeutique contre la néphropathie
CN111989103A (zh) * 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
CN110141555A (zh) * 2019-06-21 2019-08-20 江苏豪森药业集团有限公司 一种恩格列净片及其制备方法
AU2021222297B2 (en) * 2020-02-17 2026-01-22 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
US20220016078A1 (en) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Methods Of Treating Kidney Stones
KR20230112426A (ko) * 2022-01-20 2023-07-27 주식회사 대웅제약 이나보글리플로진을 포함하는 개과 동물의 비만 예방 또는 치료용 약학 조성물
KR20240045138A (ko) * 2022-09-29 2024-04-05 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물
WO2024116198A1 (fr) * 2022-12-02 2024-06-06 Syri Research Private Limited Formulation liquide orale d'empagliflozine ou de son sel pharmaceutiquement acceptable

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
NL167151C (nl) 1971-04-09 1981-11-16 Acf Chemiefarma Nv Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2758025A1 (de) 1977-12-24 1979-07-12 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS5639056A (en) 1980-07-16 1981-04-14 Kanebo Ltd Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine
JPS58164502A (ja) 1982-03-26 1983-09-29 Chugai Pharmaceut Co Ltd 除草用組成物
US4786755A (en) 1985-06-03 1988-11-22 Warner-Lambert Company Diphenic acid monoamides
US4602023A (en) 1985-06-03 1986-07-22 Warner-Lambert Company Diphenic acid monoamides
US4786023A (en) 1987-08-19 1988-11-22 Harris Leverett D Drafting implement holder
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0617613T3 (da) 1991-12-20 1996-06-17 Pfizer Porøse formgivne afgivelsesindretninger og fremgangsmåde til fremstilling deraf
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
AU1698997A (en) 1996-01-16 1997-08-11 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
JPH1085502A (ja) 1996-09-19 1998-04-07 Konica Corp 晶析方法
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
AU6024998A (en) 1997-01-15 1998-08-07 Glycomed Incorporated Aryl c-glycoside compounds and sulfated esters thereof
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
JPH11124392A (ja) 1997-10-21 1999-05-11 Sankyo Co Ltd Ｃ−グリコシル化されたアリールスズ化合物
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
JP2000219632A (ja) 1999-01-28 2000-08-08 Toyotama Koryo Kk カロリー軽減剤
US6613806B1 (en) 1999-01-29 2003-09-02 Basf Corporation Enhancement of the efficacy of benzoylbenzenes
DE60009929T2 (de) 1999-08-31 2005-03-31 Kissei Pharmaceutical Co., Ltd., Matsumoto Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6498193B2 (en) 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes
US6627611B2 (en) 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
TR200202200T2 (tr) 2000-03-17 2002-12-23 Kissei Pharmaceutical Co., Ltd. Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler.
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6627634B2 (en) 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
IL155071A0 (en) 2000-09-29 2003-10-31 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
TWI255817B (en) 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
CA2438551A1 (fr) 2001-02-15 2002-08-22 Pfizer Products Inc. Agonistes des ppar
NZ528216A (en) 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
EP1364957B1 (fr) 2001-02-26 2008-12-31 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
EP1364958B1 (fr) 2001-02-27 2010-09-08 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP3698067B2 (ja) 2001-03-30 2005-09-21 Ｊｓｒ株式会社 電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜
US6774112B2 (en) 2001-04-11 2004-08-10 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
JP2002338471A (ja) 2001-05-23 2002-11-27 Asahi Kasei Corp 勃起機能不全のための治療薬
DE10139416A1 (de) 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20030087843A1 (en) 2001-09-05 2003-05-08 Washburn William N. O-pyrazole glucoside SGLT2 inhibitors and method of use
WO2003031458A1 (fr) 2001-10-12 2003-04-17 Dana-Farber Cancer Institute Procedes de synthese de diarylmethanes
ITRM20010708A1 (it) 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
CA2473468C (fr) 2002-02-01 2011-06-21 Novo Nordisk A/S Amides d'azetidines, de pyrrolidines, de piperidines et d'azepanes aminoalkyle substitues
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003237446A1 (en) 2002-06-05 2003-12-22 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
SE0201837D0 (sv) 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1521747B1 (fr) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Modulateurs de kinase de type recepteur et procedes d'utilisation
TWI254635B (en) 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ES2345250T3 (es) 2002-08-08 2010-09-20 Kissei Pharmaceutical Co., Ltd. Derivado de pirazol en la composicion medicinal que contiene el mismo, el uso medicinal del mismo, y un intermedio para la produccion del mismo.
AU2003254903B9 (en) 2002-08-09 2008-08-21 Taisho Pharmaceutical Co., Ltd. Method for selective preparation of aryl 5-thio-beta-D-aldohexopyranosides
SI1532149T1 (sl) 2002-08-21 2010-05-31 Boehringer Ingelheim Pharma amino piperidin il ksantini njihova priprava in njihova uporaba kot zdravila
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
JP4651934B2 (ja) 2002-12-04 2011-03-16 キッセイ薬品工業株式会社 ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
MXPA05007052A (es) 2003-01-03 2005-08-18 Squibb Bristol Myers Co Metodos para producir c-aril-glucosidos como inhibidores de sglt2.
EP1597266A4 (fr) 2003-02-27 2008-02-20 Bristol Myers Squibb Co Procédé non cryogénique de production de glycosides
TWI309980B (en) 2003-03-14 2009-05-21 Yamanouchi Pharma Co Ltd C-glycoside derivatives or salts thereof
US7674486B2 (en) 2003-05-14 2010-03-09 Indus Biotech Pvt. Ltd. Synergistic composition for the treatment of diabetes mellitus
WO2005000860A2 (fr) 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions et methodes de traitement de maladie au moyen de disaccharides acetyles
FR2855756B1 (fr) 2003-06-06 2005-08-26 Ethypharm Sa Comprime orodispersible multicouche
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
US20050027236A1 (en) 2003-07-30 2005-02-03 Medtronic Ave, Inc. Aspiration catheter having a variable over-the-wire length and methods of use
TW200521131A (en) 2003-08-01 2005-07-01 Janssen Pharmaceutica Nv Substituted fused heterocyclic c-glycosides
AU2004261264A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indazole-O-glucosides
PL1651658T5 (pl) 2003-08-01 2020-11-30 Mitsubishi Tanabe Pharma Corporation Nowe związki o działaniu inhibitującym transporter zależny od sodu
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
JP4131216B2 (ja) 2003-08-20 2008-08-13 Ｊｓｒ株式会社 ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜
CA2539032A1 (fr) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Pyrazoles glucopyranosyloxy, medicaments contenant ces composes, leur utilisation et leur procede de production
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
US20050085680A1 (en) 2003-10-21 2005-04-21 Joseph Auerbach Method for industrial decontamination
WO2005049022A2 (fr) 2003-11-17 2005-06-02 Novartis Ag Utilisation de composes organiques
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE10361133A1 (de) 2003-12-22 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
BRPI0507007A (pt) 2004-01-20 2007-06-05 Novartis Ag formulação e processo de compressão direta
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE502005007196D1 (de) 2004-02-18 2009-06-10 Boehringer Ingelheim Pharma 8-ä3-amino-piperidin-1-ylü-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
CN1934103B (zh) 2004-03-04 2011-06-01 橘生药品工业株式会社 稠杂环衍生物，包含稠杂环衍生物的药物组合物及其医药用途
ZA200606792B (en) 2004-03-04 2007-12-27 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
EP2360165A3 (fr) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Derives du benzol substitues par un glucopyranosyle, medicaments renfermant ces composes, leur utilisation et leur procede de production
DE102004012676A1 (de) 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7935723B2 (en) 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
MX2007000209A (es) 2004-07-08 2007-03-30 Astellas Pharma Inc Proceso para la produccion de derivados de azuleno e intermediarios para la sintesis de los mismos.
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
CA2574451A1 (fr) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh Cyclenes substitues par d-glucopyranosyle-phenyle, medicaments contenant lesdits composes, leur utilisation et procede de production correspondant
WO2006018150A1 (fr) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh Cycles a substitution d-xylopyranosyl-phenyle, medicaments contenant ces composes, leur utilisation, et leur procede de production
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
CA2581922A1 (fr) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. Compose heterocyclique azote 1-(.beta.-d-glycopyranosyl)-3-substitue, preparation therapeutique contenant ledit compose, et emploi medical dudit compose
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524162A (ja) * 2004-12-16 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
GB0428180D0 (en) 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
DE602006009772D1 (de) 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
CA2605245A1 (fr) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Derives de glucopyranosyl-substitue (heteroaryloxy-benzyl)-benzene utilises comme inhibiteurs de sglt
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2007000445A1 (fr) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Derives de benzyle-benzene a substitution glucopyranosyle, medicaments contenant de tels composes, utilisation et production de ces derniers
TW200733966A (en) * 2005-07-27 2007-09-16 Boehringer Ingelheim Int Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
KR100780553B1 (ko) 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2620566A1 (fr) * 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Derives benzyl-benzene substitues par glucopyranosyle, medicaments contenant ces composes, leur utilisation et leur procede de preparation
RU2008113050A (ru) 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
ZA200802857B (en) 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
JOP20180109A1 (ar) 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
EP1942902A1 (fr) 2005-09-30 2008-07-16 Boehringer Ingelheim Vetmedica Gmbh Preparation pharmaceutique qui contient du meloxicam
UY30082A1 (es) 2006-01-11 2007-08-31 Boehringer Ingelheim Int Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
EP1989191B1 (fr) * 2006-02-15 2011-07-20 Boehringer Ingelheim International GmbH Dérivés de benzonitrile substitués par glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leurs applications et un procédé pour leur fabrication
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007136116A2 (fr) * 2006-05-19 2007-11-29 Taisho Pharmaceutical Co., Ltd. Composé de c-phényl glycitol
WO2007144175A2 (fr) 2006-06-16 2007-12-21 Lek Pharmaceuticals D.D. Composition pharmaceutique
PE20080991A1 (es) 2006-06-27 2008-09-05 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
EP2054426A1 (fr) 2006-08-15 2009-05-06 Boehringer Ingelheim International GmbH Dérivés de cyclopropyl-benzène à substitution glucopyranosyle, compositions pharmaceutiques contenant de tels composés, leur utilisation en tant qu'inhibiteurs de sglt et leur procédé de fabrication
MX2009001763A (es) 2006-08-17 2009-02-25 Wellstat Therapeutics Corp Tratamiento combinado para trastornos metabolicos.
CA2664095A1 (fr) 2006-09-21 2008-03-27 Boehringer Ingelheim International Gmbh Derives du difluorobenzyl-benzene substitues par glucopyranosyle, medicament contenant ces composes, leur utilisation et procede pour leur fabrication
EP2086991A1 (fr) 2006-10-27 2009-08-12 Boehringer Ingelheim International GmbH FORME CRISTALLINE DU 4-(ß-D-GLUCOPYRANOS-1-YL)-1-MÉTHYL-2-[4-((S)-TÉTRAHYDROFURAN-3-YLOXY)BENZYL]-BENZÈNE, PROCÉDÉ POUR LA PRÉPARATION DE CELLE-CI ET UTILISATION DE CELLE-CI POUR PRÉPARER DES MÉDICAMENTS
EP2079753A1 (fr) 2006-11-06 2009-07-22 Boehringer Ingelheim International GmbH Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant de tels composés, leur utilisation et procédé pour leur fabrication
MX2009004104A (es) 2006-11-09 2009-06-16 Boehringer Ingelheim Int Terapia combinada con inhibidores de sglt-2 y sus composiciones farmaceuticas.
WO2008062273A2 (fr) 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Forme posologique solide administration orale contenant une combinaison de médicaments antidiabétiques
AR065033A1 (es) 2007-01-26 2009-05-13 Boehringer Ingelheim Int Metodos para prevenir y tratar trastornos neurodegenerativos
ATE514692T1 (de) 2007-01-26 2011-07-15 Sanofi Aventis Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2010519273A (ja) 2007-02-21 2010-06-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
WO2008101938A1 (fr) 2007-02-21 2008-08-28 Boehringer Ingelheim International Gmbh Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant lesdits composés, utilisation et procédé de fabrication de ces derniers
ITFI20070042A1 (it) 2007-02-21 2008-08-22 Laboratori Guidotti Spa Formulazione farmaceutica e compressa comprendente detta formulazione.
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2008130615A1 (fr) 2007-04-20 2008-10-30 Schering Corporation Dérivés de tétrahydropyrido[4,3-d] pyrimidinone et procédés pour leur utilisation
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
EP2147008A2 (fr) 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Structures cristallines des inhibiteurs de sglt-2 et procédés pour leur préparation
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
MX2010002695A (es) 2007-09-10 2010-04-01 Janssen Pharmaceutica Nv Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101503399B (zh) 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
CA2713361A1 (fr) 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Compositions pharmaceutiques d'une association de metformine et d'un inhibiteur de la dipeptidyle peptidase-iv
US8551524B2 (en) 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
JPWO2009123194A1 (ja) 2008-04-01 2011-07-28 武田薬品工業株式会社 複素環化合物
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
CN101638423B (zh) 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 根皮苷衍生物及其制备方法和用途
WO2010045656A2 (fr) 2008-10-17 2010-04-22 Nectid, Inc. Nouvelles formes posologiques d'inhibiteur sglt2
WO2010049678A2 (fr) 2008-10-31 2010-05-06 Summit Corporation Plc Traitement de maladies utilisant de l’énergie
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
CN102307577A (zh) * 2009-02-13 2012-01-04 贝林格尔.英格海姆国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
WO2010092126A1 (fr) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant des dérivés de glucopyranosyl diphényl-méthane, sa forme posologique galénique, son procédé de préparation et ses utilisations pour une régulation glycémique améliorée chez un patient
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BRPI1013640A2 (pt) 2009-02-13 2019-09-24 Boehringer Ingelheim International Gmbh composicao farmaceutica, metodos para o tratamento e usos dos mesmos
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
JP5077786B2 (ja) 2009-04-16 2012-11-21 大正製薬株式会社 併用医薬
CN102639125A (zh) 2009-05-27 2012-08-15 百时美施贵宝公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
US20110077212A1 (en) 2009-09-25 2011-03-31 Theracos, Inc. Therapeutic uses of sglt2 inhibitors
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
JP5736377B2 (ja) 2009-09-30 2015-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １−クロロ−４−（β−Ｄ−グルコピラノス−１−イル）−２−［４−（（Ｓ）−テトラヒドロフラン−３−イルオキシ）ベンジル］ベンゼンの結晶形の調製方法
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
EP2498759B1 (fr) 2009-11-13 2018-08-01 AstraZeneca AB Formulations pour comprimés à libération immédiate
EP2552442A1 (fr) 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Composition pharmaceutique comprenant un inhibiteur sglt2 et un agoniste ppar-gamma, utilisations correspondantes
CN103370064A (zh) 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CA2826391C (fr) 2011-02-01 2017-01-24 Bristol-Myers Squibb Company Formulations pharmaceutiques comprenant un compose amine
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CA2837627A1 (fr) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Inhibiteurs de sglt-2 pour traiter des troubles metaboliques chez des patients traites avec des agents neuroleptiques
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2878625A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
CA2812519A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
US20140303098A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
US20160000816A1 (en) 2013-04-05 2016-01-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (fr) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
HUE068880T2 (hu) 2014-04-01 2025-02-28 Boehringer Ingelheim Vetmedica Gmbh Hipofízis pars intermedia diszfunkció kezelése lófélékben
KR102539788B1 (ko) 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
US20180104268A1 (en) 2015-04-30 2018-04-19 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
WO2017064193A1 (fr) 2015-10-15 2017-04-20 Boehringer Ingelheim International Gmbh Inhibiteur de sglt -2 destiné à être utilisé dans le traitement d'une myopathie métabolique
WO2017093419A1 (fr) 2015-12-04 2017-06-08 Boehringer Ingelheim International Gmbh Composition pharmaceutique, méthodes de traitement et leurs utilisations
KR20180122004A (ko) 2016-03-16 2018-11-09 베링거 인겔하임 인터내셔날 게엠베하 엠파글리플로진을 포함하는 약제학적 조성물 및 이의 용도
PL3526229T3 (pl) 2016-10-13 2021-11-02 Boehringer Ingelheim International Gmbh Sposób wytwarzania glukopiranozylo-podstawionych pochodnych benzylo-benzenu
CN109922813A (zh) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
JP2025030750A (ja) 2023-08-24 2025-03-07 パナソニックコネクト株式会社 光学ユニット及びこれを備えたレーザ発振器、レーザ加工装置
JP2025039056A (ja) 2023-09-08 2025-03-21 キヤノン株式会社 情報処理装置
JP2026007256A (ja) 2024-07-02 2026-01-16 株式会社竹中工務店 制振装置の諸元の設定方法

Also Published As

Publication number Publication date
KR20110118668A (ko) 2011-10-31
AU2010212865A1 (en) 2011-07-21
EP2396005A1 (fr) 2011-12-21
US20210283156A1 (en) 2021-09-16
MY161472A (en) 2017-04-14
AU2010212865A8 (en) 2011-11-17
UA106365C2 (ru) 2014-08-26
JP5896276B2 (ja) 2016-03-30
CO6410306A2 (es) 2012-03-30
EP2396005B1 (fr) 2025-11-26
FI2396005T3 (fi) 2026-01-20
CA2751833C (fr) 2018-11-06
US20160158264A1 (en) 2016-06-09
GEP20146120B (en) 2014-07-25
EA201101189A1 (ru) 2012-03-30
MX387010B (es) 2025-03-19
SG10201600204YA (en) 2016-02-26
AR075424A1 (es) 2011-03-30
PE20120002A1 (es) 2012-02-12
CN104138370A (zh) 2014-11-12
BRPI1013640A2 (pt) 2019-09-24
CN102316875A (zh) 2012-01-11
TN2011000413A1 (en) 2013-03-27
EP4684831A2 (fr) 2026-01-28
US20200069713A1 (en) 2020-03-05
TW201040194A (en) 2010-11-16
CA2751833A1 (fr) 2010-08-19
IL213723A0 (en) 2011-07-31
CL2011001757A1 (es) 2011-10-28
PH12016501607A1 (en) 2017-10-18
US20220313716A1 (en) 2022-10-06
US12527810B2 (en) 2026-01-20
US20170020907A1 (en) 2017-01-26
HK1203814A1 (en) 2015-11-06
NZ594485A (en) 2013-07-26
WO2010092123A1 (fr) 2010-08-19
PH12016501607B1 (en) 2024-02-21
US20110046087A1 (en) 2011-02-24
KR20170028452A (ko) 2017-03-13
EA021796B1 (ru) 2015-09-30
MX344264B (es) 2016-12-09
MX2011008214A (es) 2011-11-29
ECSP11011275A (es) 2011-09-30
SG173587A1 (en) 2011-09-29
JP2017052787A (ja) 2017-03-16
JP2015042691A (ja) 2015-03-05
WO2010092123A8 (fr) 2011-06-30
TWI478935B (zh) 2015-04-01
JP2012517975A (ja) 2012-08-09
US20120196812A1 (en) 2012-08-02
US20140031301A1 (en) 2014-01-30
AP2011005795A0 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
MA33043B1 (fr) Inhibiteur sglt-2 pour le traitement du diabete sucre de type 1, du diabete sucre de type 2, d'une intolerance au glucose ou d'une hyperglycemie
MA33046B1 (fr) Composition pharmaceutique contenant un inhibiteur sglt-2, un inhibiteur dpp- iv et facultativemenet un autre agent antidiabetique et ses utilisations
MA34640B1 (fr) Composition pharmaceutique, méthodes de traitement et ses utilisations
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
WO2008008887A3 (fr) Composés chimiques
EA201000515A1 (ru) Активаторы глюкокиназы
MY152037A (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
MX2010001560A (es) Composicion farmaceutica que comprende un inhibidor de sglt2 en combinacion con un inhibidor de dpp-iv.
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
ATE539748T1 (de) Glucokinaseaktivatoren
MA29795B1 (fr) Inhibiteurs de la dipeptidyl peptidase permetttant de traiter le diabete
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
WO2010029089A3 (fr) Polythérapie pour le traitement du diabète et des états pathologiques apparentés
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MA33241B1 (fr) Composes pour le traitement de troubles metaboliques
TW200740452A (en) Therapeutic gastrodia extracts
WO2010004283A3 (fr) Thérapie
WO2009066299A3 (fr) Utilisation du génotypage de l'haptoglobine dans le diagnostic et le traitement d'une maladie cardiovasculaire
EA200970338A2 (ru) Агонисты рецептора еро человека, композиции, способы и применение для предотвращения или лечения состояний, связанных с интолерантностью к глюкозе
WO2008021432A3 (fr) Compositions et méthodes de traitement d'états affectant le système nerveux
TW200724147A (en) Cognitive abilities improving agent